NTHI.US NeOnc Technologies Holdings, Inc. Common Stock

Healthcare Pharmaceuticals USA Stocks
4.91 USD
Close of Nov 15, 2026
2.50 11.38
Market cap
USD 142M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NTHI.US undervalued?

Graham number

The Graham number of NeOnc Technologies Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NeOnc Technologies Holdings, Inc. Common Stock fundamental analysis

No fundamental analysis for NeOnc Technologies Holdings, Inc. Common Stock yet.

NeOnc Technologies Holdings, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NeOnc Technologies Holdings, Inc. Common Stock

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, …

Full company profile